High-Altitude Neurodegeneration Cohort (HANC) Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorWest China Hospital

About this trial

Chronic physiological hypoxia has been implicated in the pathogenesis of multiple system atrophy (MSA), a fatal neurodegenerative disorder of unknown etiology. This prospective, multicenter, observational cohort study (Phase II of the High-Altitude Neurodegeneration Cohort \[HANC\] study) aims to validate the association between chronic hypoxia exposure and incident MSA risk. A total of 20,000 Han Chinese participants aged 40-75 years will be enrolled from 23 sites across China spanning an altitude gradient from 4 m to 4,500 m. All participants will undergo standardized in-person assessment including questionnaires, physical examination, blood collection, and 3-night consecutive nocturnal pulse oximetry monitoring. Participants are to be followed for incident MSA over 12 months. The primary outcome is newly diagnosed MSA (probable or definite per Gilman consensus criteria), adjudicated by an independent panel of movement disorders specialists. Secondary outcomes include the association between altitude strata and MSA incidence, the association between mean nocturnal SpO₂ and MSA incidence, and incidence rates across MSA subtypes (MSA-P and MSA-C).

Eligibility criteria

Qualifiers

Self-identified Han Chinese ethnicity

Age between 40 and 75 years (inclusive)

No prior diagnosis of parkinsonism at baseline

Permanent residence at study site location for ≥1 year prior to enrollment

Disqualifiers

Pre-existing diagnosis of Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or any other parkinsonian disorder at baseline

Severe chronic pulmonary disease (e.g., COPD GOLD stage ≥3) affecting baseline SpO₂ measurement

Severe cardiovascular disease (e.g., New York Heart Association Class III or IV heart failure)

Cognitive impairment precluding completion of study procedures

Trial design

Treatments tested in this trial

  • No Intervention: Observational Cohort

Treatment groups

20,000 Participants
are divided into 4 treatment groups

Sponsors and collaborators

West China Hospital

Lead sponsor

Affiliated Hospital of Qinghai University

Collaborator

Tibet Autonomous Region People's Hospital

Collaborator

Kunming Medical University

Collaborator

The First Affiliated Hospital of Guangzhou Medical University

Collaborator

First Affiliated Hospital of Suzhou Medical College

Collaborator

First People's Hospital of Hangzhou

Collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborator

Guiyang No.1 People's Hospital

Collaborator

Lanzhou University Second Hospital

Collaborator

The First People's Hospital of Yinchuan

Collaborator

Second Affiliated Hospital of Xi'an Jiaotong University

Collaborator

First Affiliated Hospital of Chongqing Medical University

Collaborator

The First People's Hospital of Xining City

Collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator